Pharmaceuticals, Biotechnology and Life Sciences
Study demonstrates the IONA test can accurately predict the presence of the trisomies 21, 18, and 13. Being user-friendly, cost effective and CE-marked will overcome some of the limitations of existing commercial technologies to facilitate implementation in local laboratories.
Premaitha Health plc, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT) has expanded its in-house NIPT screening service by opening a dedicated laboratory which triples clinical capacity in response to demand for the IONA test from clinicians.
Premaitha Health plc, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT), has announced the results of a study on the first-trimester detection of trisomy 21, 18 and 13 using the IONA test.
Premaitha Health has signed a distribution agreement with Antisel SA, a Greek distributor of scientific products, to provide the IONA test to clinical laboratories in the region.